Biogen Terminates its Collaboration with Catalyst Biosciences for CB 2782-PEG
Shots:
- Biogen & Catalyst Biosciences terminated their collaboration on potential treatments for dry AMD. Biogen has returned the rights for further development on CB 2782-PEG and has ended the partnership on other potential AMD treatments
- Regaining of rights to CB 2782-PEG expands CBIO’s complement portfolio in ophthalmology. Additionally, the company has full rights for another dAMD candidate, CB 4332
- In 2019, two companies collaborated under which Biogen paid Catalyst $15M up front and $340M in clinical, regulatory and commercial milestones and tiered royalties
Ref: Globe Newswire | Image: Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
